Tardive Dyskinesia: Treatment with Aripiprazole

키워드

참고문헌 (74)

1. Semple D, "Symptoms of psychiatric illness, schizophrenia and related psychosis, In Oxford handbook of psychiatry", pp.90~210 (2005), Oxford University Press
2. Correll CU, "Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies", Am J Psychiatry, 161, pp.414~425 (2004)
3. Tarsy D, "Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics", Mov Disord, 21, pp.589~598 (2006)
4. Nasrallah HA, "Focus on lower risk of tardive dyskinesia with atypical antipsychotics", Ann Clin Psychiatry, 18, pp.57~62 (2006)
5. Correll CU, "Tardive dyskinesia and new antipsychotics", Curr Opin Psychiatry, 21, pp.151~156 (2008)
6. Margolese HC, "Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia", Can J Psychiatry, 50, pp.703~714 (2005)
7. Gelder M, "Drugs and other physical treatments. Shorter Oxford textbook of psychiatry", pp.534~ (2006), Oxford University Press Inc
8. Casey DE, "Tardive dyskinesia and atypical antipsychotic drugs", Schizophr Res, 35, pp.S61~S66 (1999)
9. American Psychiatric Association, "Task Force on Tardive Dyskinesia. Tardive dyskinesia: a task force report of the American Psychiatric Association" (1992), The American Psychiatric Association
10. Margolese HC, "Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia", Can J Psychiatry, 50, pp.703~714 (2005)
11. Argo TR, "Aripiprazole, a novel atypical antipsychotic drug", Pharmacotherapy, 24, pp.212~228 (2004)
12. Duggal HS, "Aripiprazole-induced improvement in tardive dyskinesia", Can J Psychiatry, 48, pp.771~772 (2003)
13. Grant MJ, "Possible improvement of neuroleptic- associated tardive dyskinesia during treatment with aripiprazole", Ann Pharmacother, 39, pp.1953~ (2005)
14. "Aripiprazole improves neuroleptic-associated tardive dyskinesia, but it does not meliorate psychotic symptoms", Prog Neuropsychopharmacol Biol Psychiatry, 32, pp.1342~1343 (2008)
15. Shan JC, "Improvement in Pisa syndrome and tardive dyskinesia following aripiprazole treatment", J Neuropsychiatry Clin Neurosci, 21, pp.350~351 (2009)
16. Osorio RS, "Treatment of tardive dyskinesia with aripiprazole", Neurotox Res, 17, pp.432~434 (2010)
17. Sharma A, "Resolution of ziprasidone-related tardive dyskinesia with a switch to aripiprazole", Prim Care Companion J Clin Psychiatry, 7, pp.36~ (2005)
18. Witschy JK, "Improvement in tardive dyskinesia with aripiprazole use", Can J Psychiatry, 50, pp.188~ (2005)
19. Lykouras L, "Aripiprazole in the treatment of tardive dyskinesia induced by other atypical antipsychotics", Prog Neuropsychopharmacol Biol Psychiatry, 31, pp.1535~1536 (2007)
20. Caykoylu A, "Resolution of risperidone- induced tardive dyskinesia with a switch to aripiprazole monotherapy", Prog Neuropsychopharmacol Biol Psychiatry, 33, pp.571~572 (2009)
21. Swainston Harrison T, "Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder", Drugs, 64, pp.1715~1736 (2004)
22. Peña MS, "Tardive dyskinesia and other movement disorders secondary to aripiprazole", Mov Disord, 26, pp.147~152 (2011)
23. Maytal G, "Aripiprazole-related tardive dyskinesia", CNS Spectr, 11, pp.435~439 (2006)
24. Abbasian C, "A case of aripiprazole and tardive dyskinesia", J Psychopharmacol, 23, pp.214~215 (2009)
25. Evcimen YA, "Aripiprazole-induced tardive dyskinesia: the role of tamoxifen", Am J Psychiatry, 164, pp.1436~1437 (2007)
26. Zaidi SH, "Aripiprazole is associated with early onset of Tardive Dyskinesia like presentation in a patient with ABI and psychosis", Brain Inj, 22, pp.99~102 (2008)
27. Lungu C, "Tardive dyskinesia due to aripiprazole: report of 2 cases", J Clin Psychopharmacol, 29, pp.185~186 (2009)
28. Wang LJ, "of aripiprazole-associated tardive dyskinesia: report of two cases", Prog Neuropsychopharmacol Biol Psychiatry, 33, pp.746~744 (2009)
29. Schwartz T, "Aripiprazole (abilify) and tardive dyskinesia", P T, 33, pp.32~34 (2008)
30. Sajbel TA, "Aripiprazole-associated dyskinesia", Ann Pharmacother, 30, pp.200~201 (2005)
31. Klawans HL Jr, "An experimental model of tardive dyskinesia", J Neural Transm, 33, pp.235~246 (1972)
32. Tarsy D, "Pharmacologically induced behavioural supersensitivity to apomorphine", Nat New Bio, 245, pp.262~263 (1973)
33. Schatzberg AF, "American Psychiatric Press. The American psychiatric press textbook of psychopharmacology" (1995), American Psychiatric Press
34. Fibiger HC, "Neurobiological substrates of tardive dyskinesia: the GABA hypothesis", Trends Neurosci, 7, pp.462~464 (1984)
35. McGeer EG, "Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids", Nature, 263, pp.517~519 (1976)
36. Moghaddam B, "Depolarization inactivation of dopamine neurons: terminal release characteristics", Synapse, 14, pp.195~200 (1993)
37. Yamamoto BK, "Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations", J Neurosci, 14, pp.4159~4166 (1994)
38. See RE, "Chronic haloperidol, but not clozapine, produces altered oral movements and increased extracellular glutamate in rats", Eur J Pharmacol, 263, pp.269~276 (1994)
39. See RE, "Chronic haloperidol potentiates stimulated glutamate release in caudate putamen, but not prefrontal cortex", Neuroreport, 6, pp.1795~1798 (1995)
40. Andreassen OA, "Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia", Prog Neurobiol, 61, pp.525~541 (2000)
41. Barnes JM, "Behavioural pharmacology of 5-HT3 receptor ligands", Neurosci Biobehav Rev, 16, pp.107~113 (1992)
42. Egan MF, "Treatment of tardive dyskinesia", Schizophr Bull, 23, pp.583~609 (1997)
43. Seibyl JP, "Serotonin function in tardive dyskinesia", Psychiatr Annals, 19, pp.310~314 (1989)
44. Gong L, "Supersensitization of the oral response to SKF 38393 in neonatal 6-OHDA-lesioned rats is mediated through a serotonin system", J Pharmacol Exp Ther, 261, pp.1000~1007 (1992)
45. Eberle-Wang K, "A role for the subthalamic nucleus in 5-HT2C-induced oral dyskinesia", Neuroscience, 72, pp.117~128 (1996)
46. Naidu PS, "Reversal of neuroleptic-induced orofacial dyskinesia by 5-HT3 receptor antagonists", Eur J Pharmacol, 420, pp.113~117 (2001)
47. Soares-Weiser K, "Tardive dyskinesia", Semin Neurol, 27, pp.159~169 (2007)
48. Shapiro DA, "Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology", Neuropsychopharmacology, 28, pp.1400~1411 (2003)
49. Tamminga CA, "Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis", Curr Drug Targets CNS Neurol Disord, 1, pp.141~147 (2002)
50. Inoue A, "Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum", Eur J Pharmacol, 321, pp.105~111 (1997)
51. Sharma V, "Treatment-emergent tardive dyskinesia with quetiapine in mood disorders", J Clin Psychopharmacol, 23, pp.415~417 (2003)
52. raclopride, "Neuropsychopharmacology", 2002, 248~259
53. Carson WH, "Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo", Eur Neuropsychopharmacol, 10(Suppl 3), pp.S309~S310 (2000)
54. Petrie JL, "Aripiprazole, a new atypical antipsychotic: phase 2 clinical trial results", Eur Neuropsychopharmacol, 7(Suppl 2), pp.S227~ (1997)
55. E: Neuroscientific Basis and Practical Applications, "Stahl's Essential Psychopharmacology, 3", pp.2008, Stahl SM
56. Davies MA, "Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology", CNS Drug Rev, 10, pp.317~336 (2004)
57. Chrzanowski WK, "Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine", Psychopharmacology (Berl), 189, pp.259~266 (2006)
58. Meltzer HY, "Serotonin receptors: their key role in drugs to treat schizophrenia", Prog Neuropsychopharmacol Biol Psychiatry, 27, pp.1159~1172 (2003)
59. Bardin L, "Newman-Tancredi A. Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties", Neuropsychopharmacology, 31, pp.1869~1879 (2006)
60. Eskow KL, "The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy", Pharmacol Biochem Behav, 87, pp.306~314 (2007)
61. Rajarethinam R, "Use of aripiprazole in tardive dyskinesia: an open label study of six cases", World J Biol Psychiatry, 10, pp.416~419 (2009)
62. Tarsy D, "Effects of newer antipsychotics on extrapyramidal function", CNS Drugs, 16, pp.23~45 (2002)
63. Dolder CR, "Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients", Biol Psychiatry, 53, pp.1142~1145 (2003)
64. Mamo D, "Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study", Am J Psychiatry, 164, pp.1411~1417 (2007)
65. Lerer B, "Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism", Neuropsychopharmacology, 27, pp.105~119 (2002)
66. Kapur S, "Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia", Am J Psychiatry, 157, pp.514~520 (2000)
67. Wang LJ, "Courses of aripiprazole-associated tardive dyskinesia: report of two cases", Prog Neuropsychopharmacol Biol Psychiatry, 33, pp.743~744 (2009)
68. Albin RL, "The functional neuroanatomy of the basal ganglia disorders", Trends Neurosci, 12, pp.366~375 (1989)
69. Crossman AR, "A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonistinduced dyskinesia in Parkinson's disease: implications for future strategies in treatment", Mov Disord, 5, pp.100~108 (1990)
70. DeLong MR, "Primate models of movement disorders of basal ganglia origin", Trends Neurosci, 13, pp.281~285 (1900)
71. Egan MF, "Treatment of tardive dyskinesia with vitamin E", Am J Psychiatry, 149, pp.773~777 (1992)
72. Trugman JM, "Treatment of severe axial tardive dystonia with clozapine: case report and hypothesis", Mov Disord, 9, pp.441~446 (1994)
73. Lim HK, "Tardive dystonic symptoms associated with aripiprazole treatment", Prog Neuropsychopharmacol Biol Psychiatry, 32, pp.589~590 (2008)
74. Chew ML, "A model of anticholinergic activity of atypical antipsychotic medications", Schizophr Res, 88, pp.63~72 (2006)

관련 논문AI추천